The results showed that a single intravenous injection of Zybrestat, at varying doses, was well tolerated, with a decrease in polyp activity and reduction of subretinal flud and retinal edema in patients receiving Zybrestat compared to placebo

The trial showed sustained efficacy in patients receiving Vivitrol in combination with psychosocial treatment for 18 months

Inc., of Whitehouse Station, N.J., said results from a 24-week interim analysis of a 48-week Phase IIb study showed that 70.5 percent of patients (43/61) receiving its protease inhibitor Victrelis (boceprevir) in combination with peginterferon alfa and ribavirin had undetectable hepatitis C virus (HCV) compared to 34.4 percent (11/32) of patients receiving peginterferon alfa and ribavirin alone, for a treatment difference of 36.1 percent

There also was improvement in the overall SF-36 scores for patients receiving AIMPSPRO, as well as trends toward benefit in lung function measures

ActoGeniX NV, of Ghent, Belgium, said oral rinsing solution AG013 was well tolerated in a Phase Ib trial for the prevention of oral mucositis in head and neck cancer patients receiving chemo-induction therapy

The trial will enroll 100 patients with chronic low back pain due to lumbar disc degeneration in 15 centers across Australia and the U.S., comparing outcomes at six months in 60 patients receiving MPC injections against 40 patients receiving control injections

After 48 weeks of therapy, 59 percent of ritonavir-boosted elvitegravir patients achieved and maintained a viral load of less than 50 copies/mL, compared to 58 percent of patients receiving raltegravir

Medicago Inc., of Quebec City, said final Phase II data showed its H5N1 Avian influenza VLP vaccine was well tolerated and induced an immune response in 77 percent of patients receiving two doses

A Phase II trial showed median survival of 32 months in the Livatag group compared to 15 months for patients receiving best of care, but there were troubles with pulmonary adverse events, which BioAlliance said it has addressed with a new administration regimen. (See BioWorld Today, July 17, 2008

Patients receiving each of the three tested doses of bardoxolone methyl experienced a statistically significant improvement in eGFR, with increases of 5.8, 10.5 and 9.3 mL/min/1.73m2 for the 25-, 75- and 150-mg groups, respectively, relative to placebo (p = 0.002, 25 mg; p < 0.001, 75 mg and 150 mg

Corcept Therapeutics Inc., of Menlo Park, Calif., reported data demonstrating that refractory Cushing's syndrome patients receiving Corlux (mifepristone) experienced significant clinical and metabolic improvements over baseline measurements in the Phase III SEISMIC study...United Therapeutics is testing the drug in another Phase III trial, designated FREEDOM-C, in PAH patients receiving an endothelin receptor antagonist and/or a PDE-5 inhibitor, and preliminary data from that trial are expected in

The analysis showed that 63 percent of patients receiving NLX-P101 achieved moderate-to-large clinically meaningful symptom improvements at 12 months, compared to 50 percent at six months

FibroGen Inc., of San Francisco, reported results from a Phase II trial of FG-4592 for end-stage renal disease in patients receiving hemodialysis

More patients receiving XEN402 than placebo reported greater than 30 percent (p = 0.049) and 50 percent (p = 0.008) pain reductions

Additionally, while not powered to demonstrate statistically significant clinical activity, data from the trial showed that patients receiving OTO-104 experienced greater reductions in vertigo frequency and tinnitus compared to patients receiving placebo

Five-year findings also showed that an estimated 72 percent of patients receiving alemtuzumab were relapse-free compared to 41 percent of patients taking Rebif (interferon beta-1a, Merck Serono SA) and an estimated 87 percent of patients in the alemtuzumab group were free of sustained accumulation of disability vs. 62 percent in the Rebif group...Preliminary data from the QualiCop study indicated a significant improvement of cognitive function and depressive symptoms over 24 months in patients

BioAlliance Pharma SA, of Paris, updated its preliminary survival data from Livatag (doxorubicin Transdrug) in hepatocellular carcinoma, with Phase II follow-up results showing a median survival of 32 months in the Livatag group compared to 15 months for patients receiving best of care

Achillion Pharmaceuticals Inc., of New Haven, Conn., reported that top-line results from its Phase IIa trial of ACH-1625 dosed once daily (QD) in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), a current standard of care in patients with chronic hepatitis C infection, demonstrated that 75 percent to 81 percent of patients receiving ACH-1625 achieved rapid virologic response with a promising safety and tolerability profile

Cellerant Therapeutics Inc., of San Carlos, Calif., started a Phase I/II trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia